Degradation of EGFR Contributes to Anti-Cancer Effects of HDAC Inhibitor in Head and Neck Cancer

dc.contributor.authorDuncan, Leslie
dc.contributor.authorJensen, Caleb
dc.contributor.authorHe, Leilei
dc.contributor.authorLang, Liwei
dc.contributor.departmentBiological Sciences, Oral Biology & Diagnostic Sciences, Georgia Cancer Centeren_US
dc.date.accessioned2020-05-05T21:53:55Z
dc.date.available2020-05-05T21:53:55Z
dc.date.issued5/5/2020
dc.description.abstractThis item presents the abstract for a poster presentation at the 21st Annual Phi Kappa Phi Student Research and Fine Arts Conference.en_US
dc.description.advisorYong Tengen_US
dc.description.sponsorshipAugusta University Provost’s Office and the Translational Research Program of the Department of Medicineen_US
dc.identifier.doihttp://doi.org/10.21633/issn.2380.5064/s.2020.03.02.05
dc.identifier.urihttp://hdl.handle.net/10675.2/623331
dc.language.isoen_USen_US
dc.publisherAugusta University Librariesen_US
dc.relation.ispartofseriesVolume 3, Issue 2en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleDegradation of EGFR Contributes to Anti-Cancer Effects of HDAC Inhibitor in Head and Neck Canceren_US
dc.typeOtheren_US
refterms.dateFOA2020-05-05T21:53:56Z

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Duncan_vol3_issue2.pdf
Size:
284 KB
Format:
Adobe Portable Document Format
Description: